Clinical Trial Update: Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT) [Phase 3]

View source ↗

Summary

Phase 3 trial of depigmented and polymerized Olea europaea allergen extract (GPIT) for allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Rhinoconjunctivitis

Drugs mentioned

• GPIT (Depigmented and polymerized Olea europaea pollen extract)

Snippet

Sponsor: Laboratorios Leti, S.L. | Conditions: Allergy, Rhinoconjunctivitis | Phase 3 | Status: COMPLETED